Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval
Earlier this year, Ionis’ CEO Brett Monia said that Tryngolza (olezarsen) would become the company’s first fully owned blockbuster drug,…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion
Merck KGaA has agreed to acquire life sciences company Bio-Techne Corporation for $11.3bn, representing one of the largest financial outlays…
-
Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal
Just a year after spinning out from Scorpion Therapeutics, Antares Therapeutics has secured a big pharma partner to help advance…
-
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy
The US Food and Drug Administration (FDA) will reconsider Regenxbio’s gene therapy for Hunter syndrome after determining the preexisting package…
-
Moderna’s mRNA flu vaccine passes FDA AdCom, review underway
Moderna’s mRNA vaccine for influenza prevention has passed a US Food and Drug Administration (FDA) Advisory Committee (AdCom) meeting, meaning…
-
Biopharma industry confidence at highest in years despite geopolitical headwinds
Biopharma executives’ confidence in the industry has reached its highest point in four years, reflecting a successful navigation through a…
-
UniQure to seek approval of Huntington’s gene therapy after FDA U-turn
UniQure has confirmed it will submit its Huntington’s disease gene therapy for regulatory review, after the US Food and Drug…
-
Biopharma bounces back as M&A impetus fuels recovery
Following the largest dealmaking quarter in six years, PwC analysts have empirically stated that the biopharma ecosystem is “back to…
-
Cystic Fibrosis Foundation backs Israeli biotech with $13m to develop inhaled drug
The Cystic Fibrosis Foundation will supply up to $13m of funding to SpliSense, helping the biotech continue development of its…
-
Younger UK children to benefit from new dose of nasal spray allergy drug
Younger children in the UK will now have a needle-free option to treat serious allergic reactions after the UK’s Medicines…